### Edgar Filing: Ohr Pharmaceutical Inc - Form 8-K

Ohr Pharmaceutical Inc Form 8-K December 15, 2017

#### **UNITED STATES**

#### SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

#### FORM 8-K

### Current Report

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): December 15, 2017

## Ohr Pharmaceutical, Inc.


(Exact Name of Registrant as Specified in Its Charter)

Delaware 333-88480 46-5622433 (State or Other Jurisdiction (Commission (I.R.S. Employer of Incorporation) File Number) Identification No.)

800 Third Avenue, 11<sup>th</sup> Floor, New York, NY 10022 (Address of Principal Executive Offices) (Zip Code)

(212) 682-8452

#### Edgar Filing: Ohr Pharmaceutical Inc - Form 8-K



Exchange Act.

### Edgar Filing: Ohr Pharmaceutical Inc - Form 8-K

The information in this Current Report on Form 8-K, including Exhibit 99.1 and the information therefrom incorporated in Item 2.02 by reference to Exhibit 99.1, are being furnished, and shall not be deemed "filed," for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liability under that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.

#### Item 2.02 Results of Operations and Financial Condition

On December 15, 2017, Ohr Pharmaceutical, Inc., a Delaware corporation, issued a press release announcing its results for the fiscal year ended September 30, 2017. This press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

#### Item 9.01 Financial Statements and Exhibits.

(d) Exhibits:

99.1 Press release, dated December 15, 2017

## **SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

OHR PHARMACEUTICAL, INC (Registrant)

Date: December 15, 2017 By:/s/ Sam Backenroth
Sam Backenroth
Chief Financial Officer

# EXHIBIT INDEX

Exhibit No. Description

99.1 Press release, dated December 15, 2017